331 related articles for article (PubMed ID: 9195603)
1. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.
Danysz W; Parsons CG; Kornhuber J; Schmidt WJ; Quack G
Neurosci Biobehav Rev; 1997 Jul; 21(4):455-68. PubMed ID: 9195603
[TBL] [Abstract][Full Text] [Related]
2. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover.
Quack G; Hesselink M; Danysz W; Spanagel R
J Neural Transm Suppl; 1995; 46():97-105. PubMed ID: 8821045
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo.
Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W
Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022
[TBL] [Abstract][Full Text] [Related]
4. Trapping channel block of NMDA-activated responses by amantadine and memantine.
Blanpied TA; Boeckman FA; Aizenman E; Johnson JW
J Neurophysiol; 1997 Jan; 77(1):309-23. PubMed ID: 9120573
[TBL] [Abstract][Full Text] [Related]
5. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
Kornhuber J; Weller M; Schoppmeyer K; Riederer P
J Neural Transm Suppl; 1994; 43():91-104. PubMed ID: 7884411
[TBL] [Abstract][Full Text] [Related]
6. [New therapeutic possibilities with low-affinity NMDA receptor antagonists].
Kornhuber J; Weller M
Nervenarzt; 1996 Jan; 67(1):77-82. PubMed ID: 8676993
[TBL] [Abstract][Full Text] [Related]
7. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration.
Hesselink MB; Smolders H; De Boer AG; Breimer DD; Danysz W
Behav Pharmacol; 1999 Feb; 10(1):85-98. PubMed ID: 10780305
[TBL] [Abstract][Full Text] [Related]
8. Suppression by memantine and amantadine of synaptic excitation intrastriatally evoked in rat neostriatal slices.
Rohrbacher J; Bijak M; Misgeld U
Neurosci Lett; 1994 Nov; 182(1):95-8. PubMed ID: 7891899
[TBL] [Abstract][Full Text] [Related]
9. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
10. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis.
Wenk GL; Danysz W; Mobley SL
Eur J Pharmacol; 1995 Oct; 293(3):267-70. PubMed ID: 8666045
[TBL] [Abstract][Full Text] [Related]
11. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine.
Parsons CG; Panchenko VA; Pinchenko VO; Tsyndrenko AY; Krishtal OA
Eur J Neurosci; 1996 Mar; 8(3):446-54. PubMed ID: 8963435
[TBL] [Abstract][Full Text] [Related]
12. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist.
Karcz-Kubicha M; Lorenz B; Danysz W
Neuropharmacology; 1999 Jan; 38(1):109-19. PubMed ID: 10193902
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Fredriksson A; Danysz W; Quack G; Archer T
J Neural Transm (Vienna); 2001; 108(2):167-87. PubMed ID: 11314771
[TBL] [Abstract][Full Text] [Related]
14. [A comparative study of the central H-cholinergic-blocking and NMDA-blocking actions of MK-801, memantin, amantadine, pyrilen and IEM-1754 in experiments on intact rats].
Gmiro VE; Serdiuk SE
Eksp Klin Farmakol; 2000; 63(2):16-20. PubMed ID: 10834088
[TBL] [Abstract][Full Text] [Related]
15. Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome?
Müller T; Riederer P; Kuhn W
Expert Rev Clin Pharmacol; 2023 Feb; 16(2):101-107. PubMed ID: 36726198
[TBL] [Abstract][Full Text] [Related]
16. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
[TBL] [Abstract][Full Text] [Related]
17. Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice.
Escher T; Call SB; Blaha CD; Mittleman G
Psychopharmacology (Berl); 2006 Sep; 187(4):424-34. PubMed ID: 16835770
[TBL] [Abstract][Full Text] [Related]
18. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Bibbiani F; Oh JD; Kielaite A; Collins MA; Smith C; Chase TN
Exp Neurol; 2005 Dec; 196(2):422-9. PubMed ID: 16203001
[TBL] [Abstract][Full Text] [Related]
19. Investigation on possible antioxidative properties of the NMDA-receptor antagonists ketamine, memantine, and amantadine in comparison to nicanartine in vitro.
Lupp A; Kerst S; Karge E; Quack G; Klinger W
Exp Toxicol Pathol; 1998 Sep; 50(4-6):501-6. PubMed ID: 9784030
[TBL] [Abstract][Full Text] [Related]
20. [Ketamine inhibits n-methyl-d-aspartate (NMDA) receptor mediated acetylcholine release from rabbit caudate nucleus slices].
Feuerstein TJ
Anaesthesist; 1994 Nov; 43 Suppl 2():S48-51. PubMed ID: 7840414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
